Phase 2 Trial of HY209gel in Atopic Dermatitis Patients

Completed · Phase 2 · Has a placebo group

Conditions studied: Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp

In brief

This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.

Key facts

Study ID

NCT06024499

Run by

Shaperon

People needed

210

Starts

2024-03-01

Expected to finish

2026-04-13

Last updated by the study team

2026-06-24

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cahaba Dermatology Skin Health Center — Birmingham, Alabama, United States
• RAOOF MD Dermatology — Encino, California, United States
• L.A. Universal Research Center, Inc. — Los Angeles, California, United States
• Zenith Research Inc. — Los Angeles, California, United States
• Continental Clinical Solutions, LLC — Towson, Maryland, United States
• Revival Research Institute, LLC — Southfield, Michigan, United States
• Sadick Dermatology — New York, New York, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
• Gachon University Gil Medical Center — Seoul, South Korea
• Seoul National University Bundang Hospital — Seoul, South Korea
• Seoul National University Hospital — Seoul, South Korea
• Severance Hospital, Yonsei University Health System — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.